Zhao, Helong
Deininger, Michael W. http://orcid.org/0000-0002-2987-1331
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA257602-01, R01 CA178397-05, P30 CA042014)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 10 August 2020
Accepted: 19 August 2020
First Online: 10 September 2020
Compliance with ethical standards
:
: MWD is an advisory board member of Blueprint, Takeda, Incyte, and Sangamo, is a consultant for Blueprint, Fusion Pharma, Medscape, Novartis, Sangamo and DisperSol, and receives research funding from Blueprint, Takeda, Novartis, Incyte, SPARC, Leukemia & Lymphoma Society, and Pfizer.